2.00
0.05 (2.56%)
| Penutupan Terdahulu | 1.95 |
| Buka | 2.01 |
| Jumlah Dagangan | 6,677 |
| Purata Dagangan (3B) | 549,530 |
| Modal Pasaran | 3,502,326 |
| Harga / Buku (P/B) | 0.950 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 14 May 2025 |
| EPS Cair (TTM) | -41.44 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.13% |
| Nisbah Semasa (MRQ) | 1.90 |
| Aliran Tunai Operasi (OCF TTM) | -13.43 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -7.63 M |
| Pulangan Atas Aset (ROA TTM) | -122.21% |
| Pulangan Atas Ekuiti (ROE TTM) | -259.00% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Indaptus Therapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.0 |
| Purata | -0.50 |
|
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 36.87% |
| % Dimiliki oleh Institusi | 13.08% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Pine Valley Investments Ltd Liability Co | 31 Dec 2024 | 1,568 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 17 Nov 2025 | Pengumuman | Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit |
| 12 Nov 2025 | Pengumuman | Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |